Abstract
Multidrug-resistant (MDR) Pseudomonas aeruginosa infection causes significant mortality among patients with hematologic malignancies and hematopoietic-cell transplant recipients. Ceftolozane-tazobactam (C-T) is a novel therapeutic option for MDR-P. aeruginosa infections but clinical experience in these patients is limited. We report favorable clinical outcomes and lack of limiting toxicities using C-T monotherapy to treat invasive MDR-P. aeruginosa infections in these patient populations.
Original language | English (US) |
---|---|
Pages (from-to) | 431-434 |
Number of pages | 4 |
Journal | Infection |
Volume | 46 |
Issue number | 3 |
DOIs | |
State | Published - Jun 1 2018 |
Keywords
- Ceftolozane-tazobactam
- Hematologic malignancy
- Hematopoietic-cell transplant
- Pseudomonas aeruginosa
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases